A Glimpse Into The Expert Outlook On Harmony Biosciences Through 6 Analysts
Portfolio Pulse from Benzinga Insights
Harmony Biosciences (NASDAQ:HRMY) has been evaluated by 6 analysts over the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target is now $38.5, down 30.63% from the previous $55.50. Recent analyst actions include maintaining, raising, and lowering ratings and price targets. Harmony Biosciences is a commercial-stage pharmaceutical company with a focus on rare neurological diseases. Financially, the company has shown strong performance with a revenue growth rate of 36.74%, a net margin of 24.0%, an ROE of 7.96%, an ROA of 5.0%, and a low debt-to-equity ratio of 0.41.
January 02, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Harmony Biosciences has received mixed analyst ratings with a downward revision in the average price target to $38.5. The company's strong financial performance may counterbalance the negative sentiment from the lowered price targets.
While the average price target for HRMY has been lowered, indicating a bearish sentiment, the company's strong financial performance in terms of revenue growth, net margin, ROE, and ROA, as well as a low debt-to-equity ratio, suggest a solid underlying business. This could help maintain investor confidence despite the reduced price targets.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100